Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02630030 · ClinicalTrials.gov registry record · Early Phase 1
Phase 0 Analysis of Ixazomib (MLN9708) in Patients With Glioblastoma
A Early Phase 1 study, sponsored by Emory University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 3
- Enrollment target
NCT02630030 is a Early Phase 1 study that has completed, run by Emory University. The registered enrollment target is 3 participants.
The verdict
NCT02630030, a Early Phase 1 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This phase 0 trial studies ixazomib citrate in treating patients with glioblastoma that has spread or returned after period of improvement who are planning to undergo surgery. When given by mouth, ixazomib may be able to reach tumor cells in the brain. Studying samples of tissue, blood, and plasma in the laboratory from patients receiving ixazomib may help doctors learn more about the effects of ixazomib on the cells. It may also help doctors understand how well patients will respond to treatment.
Interventions
- DRUG Ixazomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2016-03-24 |
| Est. Completion | 2020-09-03 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02630030
The ClinicalTrials.gov registry entry for NCT02630030 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ixazomib is the first listed.
NCT02630030 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02630030 about?
NCT02630030 is a clinical study titled "Phase 0 Analysis of Ixazomib (MLN9708) in Patients With Glioblastoma". This phase 0 trial studies ixazomib citrate in treating patients with glioblastoma that has spread or returned after period of improvement who are planning to undergo surgery. When given by mouth, ixazomib may be able to reach tumor cells in the brain. Studying samples of tissue, blood, and plasma i...
What is the current status of trial NCT02630030?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 3 participants. The study started on 2016-03-24. Estimated completion is 2020-09-03.
What interventions are being tested in trial NCT02630030?
The interventions under investigation include: Ixazomib (DRUG).
Who is sponsoring clinical trial NCT02630030?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.